TARA

Protara Therapeutics, Inc.
CAPPED RATING

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Protara Therapeutics, Inc. (TARA) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D).

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.4 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
D
Factor Score 1.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.5
EV / EBITDA -0.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -36.4%
Price Return 12M -52.3%
Catalyst Signal 0.00
Market Cap $155.8M
TTM Revenue N/A
Price / Sales N/A
ROE -57.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) D (1.4) D+ (1.8) D (1.3) C+ (2.6) C- (1.9)
2026-11-08 A- (3.9) D (1.4) D+ (1.8) D (1.2) C+ (2.6) C (2.2)
2026-11-01 C+ (2.5) D (1.4) C- (1.9) D (1.3) C+ (2.7) C- (2.0)
2026-10-25 B+ (3.7) D (1.4) C- (1.9) D (1.3) C+ (2.6) C (2.2)
2026-10-18 B+ (3.7) D (1.4) C- (1.9) D (1.4) C+ (2.6) C (2.2)
Page 1 of 4